# Superficial vein thrombosis

Condition · id `cardio:superficial-vein-thrombosis` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Superficial venous thrombosis; Superficial thrombophlebitis

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

Superficial vein thrombosis is a blood clot with inflammation in a superficial vein. MeSH describes thrombophlebitis as inflammation of a vein associated with a blood clot. An open-access review (Healthcare, 2024) calls it a relatively common event with several possible causes. It says the condition has been seen as benign but is not free of complications, because it can extend to the deep veins and travel to the lungs. A second review (2024) says superficial vein thrombosis of the lower limbs is linked to deep vein thrombosis or pulmonary embolism in up to one fourth of cases. The first review names varicose veins as the primary risk factor for it in the leg. The second review names fondaparinux, low-molecular-weight heparin and rivaroxaban in its discussion of treatment. This page gives no advice on treatment.

## Technical summary

MeSH descriptor D013924 (Thrombophlebitis) is a broad match: its scope note describes inflammation of a vein with a clot and does not limit it to superficial veins. The 2024 comprehensive review (Healthcare) gives an incidence of about 0.3 to 1.5 for every 1000 person-years and a prevalence of about 3 to 11 percent, depending on the population studied, and says an ultrasound examination is recommended to judge the extent of the clot and to exclude involvement of the deep veins. The 2024 treatment review gives the aims of treatment as relieving local symptoms and preventing recurrence or extension into deep vein thrombosis or pulmonary embolism. The text rests on the MeSH scope note and these two reviews.

## Connected pages

- Filed under this front: Medicines (`cardio:front-medicines`)
- A review says the clot can extend to the deep veins: Deep vein thrombosis (`cardio:deep-vein-thrombosis`)
- A review links superficial vein thrombosis of the lower limbs to pulmonary embolism: Pulmonary embolism (`cardio:pulmonary-embolism`)
- A review names varicose veins as the primary risk factor in the leg: Varicose veins (`cardio:varicose-veins`)
- Named in a review of treatment: Fondaparinux (`cardio:fondaparinux`)
- Named in a review of treatment: Heparins and low-molecular-weight heparins (`cardio:heparins-and-low-molecular-weight-heparins`)
- Named in a review of treatment: Rivaroxaban (`cardio:rivaroxaban`)

## Provenance

Content hash: 684801e3f4fc2551cfd3468d7d9ca47c6d6e7c9b5df4dafd8ebdce6dfe57dfdb
Last substantive edit: 2026-11-18
Evidence last checked: 2026-11-18
